Department of Large Animal Clinical Sciences (Erickson, Waldner, Snyder) and Department of Microbiology (Sniatynski, Ellis) and Prairie Diagnostic Services (Bravo Araya), Western College of Veterinary Medicine, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4.
Can Vet J. 2024 Aug;65(8):791-801.
This study compared clinical and immunological responses to coinfection challenge of beef calves mucosally primed and differentially boosted with commercial combination vaccines containing antigens against bovine coronavirus (BCoV), bovine parainfluenza virus Type 3 (BPIV3), and bovine respiratory syncytial virus (BRSV).
Nineteen commercial beef heifers.
At birth, calves were mucosally (IN) primed with modified-live virus (MLV) vaccines, differentially boosted by injection of either combination MLV (IN-MLV) or inactivated virus (IN-KV) vaccines at a mean age of 44 d, and then challenged by coinfection with BCoV, BPIV3, and BRSV at weaning.
Both groups were similarly protected from clinical disease and had anamnestic neutralizing antibody responses to all 3 viruses. The IN-KV group shed more BCoV, and less BPIV3 and BRSV, than the IN-MLV group.
These data indicated similar clinical and immunological protection between IN-MLV and IN-KV; however, shed of virus varied.
Whereas boosting with KV or MLV appeared to have similar efficacy, viral shed differences may affect disease control.
本研究比较了经黏膜接种商业联合疫苗（针对牛冠状病毒（BCoV）、牛副流感病毒 3 型（BPIV3）和牛呼吸道合胞体病毒（BRSV）的抗原）对牛犊进行黏膜初免和差异加强免疫后，对共感染挑战的临床和免疫反应。
19 头商业肉牛小母牛。
犊牛出生时经黏膜（IN）接种改良活病毒（MLV）疫苗，在平均 44 日龄时通过注射联合 MLV（IN-MLV）或灭活病毒（IN-KV）疫苗进行差异加强免疫，然后在断奶时进行 BCoV、BPIV3 和 BRSV 的共感染挑战。
两组在临床疾病方面均得到类似的保护，并且对所有 3 种病毒均有回忆性中和抗体反应。IN-KV 组比 IN-MLV 组排出更多的 BCoV，排出的 BPIV3 和 BRSV 较少。
这些数据表明 IN-MLV 和 IN-KV 之间具有相似的临床和免疫保护作用；然而，病毒排出量有所不同。
尽管 KV 或 MLV 加强免疫似乎具有相似的效果，但病毒排出的差异可能会影响疾病控制。
